Alendronic Acid API Powder

Alendronic acid is used to treat osteoporosis. It is a type of drug known as a bisphosphonate. It is used to prevent bone loss in women after they have been through the menopause, and bone loss in men and in people taking steroids. Treatment of osteoporosis in post-menopausal wome to prevent fractures. Treatment of osteoporisis in men to preven fractures. Treatment of glucocorticoid-induced osteoporosis and prevention of bone loss in post-menopausal women considered at risk of developing osteoporosis.

Alendronate Sodium A bisphosphonate used to prevent and treat osteoporosis, Pagets disease, and bone loss in postmenopausal women and steroid therapy.

Alendronate is a nitrogen-containing, second generation bisphosphonate. Bisphosphonates were first used to treat Pagets disease in 1971. This class of medications is comprised of inorganic pyrophosphate analogues that contain non-hydrolyzable P-C-P bonds. Similar to other bisphosphonates, alendronate has a high affinity for bone mineral and is taken up during osteoclast resorption. Alendronate inhibits farnesyl pyrophosphate synthetase, one of the enzymes in the mevalonic acid pathway involved in producing isoprenoid compounds that are essential for post-translational modification of small guanosine triphosphate (GTP)-binding proteins, such as Rho, Ras and Rab. Inhibition of this process interferes with osteoclast function and survival. Alendronate is used for the treatment of osteoporosis and Pagets disease.

CAS No. 66376-36-1CAS Name (4-Amino-1-hydroxybutylidene)bisphosphonic acidAdditional Name a-hydroxy-d-aminobutylidenediphosphonic acidMolecular wt. 249.10Chemical Composition C H NO P4 13 17 2Test SpecificationDescription White Crystalline PowderIdentification A. I. R. TESTHeavy Metals Limit : Max .20PPMLoss on Drying (By Kf) 1% W/W4-Aminobutanoic acid (by TLC) Limit : Max.0.5%Phosphite Limit : Max.0.5%Assay (Titration) Limit: 98% to 102%

Alendronate Sodium API is a nitrogen-containing bisphosphonate active pharmaceutical ingredient (API) used primarily in the treatment and prevention of osteoporosis. It acts as a potent inhibitor of bone resorption by specifically binding to hydroxyapatite crystals in bone. Once internalized by osteoclasts, it disrupts the mevalonate pathway, leading to osteoclast apoptosis and a net decrease in bone turnover. This increases bone mineral density and reduces fracture risk. The API is typically formulated as immediate-release or effervescent tablets for oral administration, requiring strict dosing instructions (e.g., with plain water, remaining upright) to ensure bioavailability and minimize the risk of esophageal irritation.

Alendronate Sodium

Alendronate Sodium